Leukemia m2 is a subtype of acute myeloid leukemia, which is a malignant disease of the myeloid hematopoietic stem cells, commonly known as blood cancer. Internationally, acute leukemia is often divided into acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, acute myeloid leukemia, acute leukemia m2, which is one of the acute non-lymphoblastic leukemia, and granulocytic leukemia partially differentiated, characterized by an abnormal increase in primitive myeloid cells in the peripheral blood of the bone marrow. The main clinical manifestations are anemia, hemorrhage, infection, infiltration of other organs, metabolic abnormalities, and so on. Most cases of acute leukemia are very critical and the prognosis is more dangerous, if not treated in time, it can often be life-threatening and the average survival period is not more than 3 months, but nowadays, due to the continuous renovation of chemotherapy, targeted therapy, immunotherapy, stem cell transplantation and other technologies, the prognosis of leukemia has been greatly improved, so if a clear diagnosis is made, it is important to consult a doctor in time to get the best treatment. Therefore, if a clear diagnosis is made, it is important to consult a doctor in time to get the best treatment.